-
Cola consumption, but not caffeine per se, was associated with increased risk of developing hypertension over a 12-year period.
-
Tipranavir is a recently approved protease inhibitor for the treatment of HIV-1 infections. It is a selective non-peptide HIV-1 protease inhibitor for treatment-experienced adults with resistance to multiple protease inhibitors. Tipranavir is marketed by Boehringer Ingelheim as Aptivus®.
-
Only minimal differences in efficacy for treatment of major depressive disorders were found when SSRIs and 4 other 2nd generation antidepressants were compared to each other in randomized controlled trials, and almost all of the trials were sponsored by pharmaceutical companies.
-
Sustained release bupropion treatment is an efficacious aid to smoking cessation for patients at risk for and with chronic obstructive pulmonary disease.
-
Esomeprazole 20 mg and 40 mg daily improve upper GI symptoms occurring during NSAID therapy including selective COX-2 inhibitors.
-
Death rates in the year after bariatric surgery were high (4.6%), and were higher for men, for those older than 65, and for those whose surgeon performed fewer than 35 such operations a year.
-
The use of an attenuated varicella zoster virus vaccine, many times more potent than that used in children for the prevention of chickenpox, was effective in the prevention of both herpes zoster and postherpetic neuralgia in individuals 60 years of age and older.
-
The FDA has approved nelarabine for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic leukemia (T-LBL). Nelarabine was approved under the FDAs accelerated approval program. It received an Orphan Designation because it is for a rare disease affecting less than 200,000 in the United States. Nelarabine is marketed by GlaxoSmithKline as Arranon®.
-
Should Empiric Treatment be Given to women with UTI Sx but negative U/A?; Is Routine Fundoscopy Worth the Bother in Hypertension?; Autoantibody Signatures in Prostate Cancer
-
Neuraminidase inhibitors are a class of antivirals that have activity against both influenza A and B viruses. Influenza neuraminidase cleaves terminal sialic acid residues and damages the receptors recognized by viral hemagglutinin, thereby facilitating release of virus from infected cells. In the presence of a neuraminidase inhibitor, release of virus from infected cells is impaired and the progeny viruses that are freed clump together, as sialic acid has not been cleaved.
